Matt Larew: No, I guess it was maybe not intentionally big. But I think you addressed [indiscernible] on what I was kind of hoping to get at. So the second one would be you referenced, I think Dan’s question around sales versus lease of instruments that you’re willing to make changes as appropriate health partners. So that may be an internal change in response to the macro environment. Have you noticed or were you aware of any sort of external changes, be it competitive behavior around getting away instruments or cutting prices? Have you noticed any price pressure or additional competition kind of in a changing macro environment?
Doug Doerfler: I think our value proposition still holds true. I mean it’s all about reducing risk and accelerating development. And those are two things that all these companies obviously, want to do. One indication is our gross margins, 90% gross margins in the quarter. And I think that’s a tribute to our ability to maintain pricing in the marketplace. So just to give you those kind of data points right now, we’re feeling pretty comfortable with where we are in terms of competition. We’re not really seeing anything in kind of in our area. We have mentioned [indiscernible] in the past. We’ve seen a lot come in and out. A lot of companies that are trying to get into the space, kind of newer companies that are trying to figure out how they can take us on.
I think that’s just a healthy environment. It points to the — I think it points to the importance of non-viral cell engineering in the future. And I would project that after exa-cel gets approved, there will even be more people interested in trying to figure out how big that market is and how they can participate. That said, we’re in a great position with our partners and our technology, and we’re continuing to be the go-to premier company in this space.
Matt Larew: Okay. The last one is just a follow-up on VLx. Earlier this year on the fourth quarter call, you mentioned that there was — it was revenue generated in ’22 that, that would grow in 2023. We’re now a little over a year into the launch. So I think it’s just sort of an early access focused launch. But is there anything you can share with us about how much VLx is contributing to the financial model at this point or is that something that you may be able to start sharing next year?
Doug Doerfler: I think we’ll be much more comfortable sharing it next year. Ali is on board, he’s doing a great job, really increasing the visibility of the offering to high-profile clients and really just talking about how disruptive this technology is and how important it is going to be for early-stage development of these programs. So I think we’ll be able to provide a much more fulsome view of the strategy and provide some expectations when we do so in ‘24.
Matt Larew: Okay. Thank you.
Operator: Thank you. One moment, please. And our next question comes from Steven Mah with TD Cowen.
Steven Mah: Great. Thanks for the questions. Maybe a follow-up to Hannah’s questions on SPL adds. Maybe I’ll ask it in a different way. This is more with regards to the funnel of your SPL leads has the potential success of exa-cel? Has it led to more business development inbounds or tractions with potential partners?
Doug Doerfler: I think the pipeline itself continues to be really, really strong and great. We’re having excellent discussions with folks. Some of them would fall into the same camp that we’ve been talking about, where they have they’re early stage development companies, and they really don’t have the financial support to move into the clinic. And so that’s — that can pause our SPLs, although I think it’s fair to say that we’ve got other companies that we’re working with that have that same situation and they’re moving forward. I think my sense is that when exa-cel gets approved. I mean I think you heard in — you heard it in the — if you — we heard it, we did — we heard it in the AdCom meeting that there was very little concern about the manufacturing of that product.
